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The mucous gel maintains a neutral microclimate at the epithelial cell surface, which may 
play a role in both the prevention of  gastroduodenal injury and the provision of  an 
environment essential for epithelial restitution and regeneration after injury. Enhancement 
of  the components o f  the mucous barrier by sucralfate may explain its therapeutic efficacy 
for upper gastrointestinal tract protection, repair, and healing. We studied the effect o f  
sucralfate and its major soluble component, sucrose octasulfate (SOS), on the synthesis 
and release of  gastric mucin and surface active phospholipid, utilizing an isolated canine 
gastric mucous cells in culture. We correlated these results with the effect o f  the agents on 
mucin synthesis and secretion utilizing explants o f  canine fundus in vitro. Sucralfate and 
SOS significantly stimulated phospholipid secretion by isolated canine mucous cells in 
culture (123% and 112% of  control, respectively). Indomethacin pretreatment significantly 
inhibited the effect o f  sucralfate, but not SOS, on the stimulation o f  phospholipid release. 
Administration of  either sucralfate or SOS to the isolated canine mucous cells had no effect 
upon mucin synthesis or secretion using a sensitive immunoassay. Sucralfate and SOS did 
not stimulate mucin release in the canine explants; sucralfate significantly stimulated the 
synthesis o f  mucin, but only to 108% of  that observed in untreated explants. No increase in 
PGE 2 release was observed after sucralfate or SOS exposure to the isolated canine mucous 
cells. Our results suggest sucralfate affects the mucous barrier largely in a qualitative 
manner. No increase in mucin secretion or major effect on synthesis was noted, although 
a significant increase in surface active phospholipid release was observed. The lack o f  dose 
dependency of  this effect, along with the results o f  the PGE 2 assay, suggests the drug may 
act through a non-receptor-mediated mechanism to perturb the cell membrane and release 
surface active phospholipid. The enhancement o f  phospholipid release by sucralfate to 
augment the barrier function of  gastric mucus may, in concert with other effects o f  the drug, 
strengthen mucosal barrier function. 
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The maintenance of the integrity of the gastroduo- 
denal mucosa is complex. Of critical importance is 
the mucous layer, which is composed o fa  mucin gel 
associated with other proteins and lipids into which 
a bicarbonate-rich fluid is secreted forming a pro- 
tective pH gradient (1). The ability of the mucous 
gel to maintain a neutral microclimate at the cell 
surface may play a role not only in the prevention of 
injury to the intact epithelium but also in the gen- 
eration of an environment suitable for epithelial 
restitution and regeneration after injury. Long-term 
preservation of this mucosal barrier depends on 
continued synthesis and secretion of its compo- 
nents: mucin, lipids, and bicarbonate. Enhance- 
ment of the components of the mucosal barrier by 
sucralfate may explain its effect in upper gastroin- 
testinal tract protection, repair, and healing (2). 
The lipid component of the mucous gel appears to 
be critical for its function as a physiological barrier. 
Phospholipids, while accounting for a small per- 
centage of the total lipids associated with gastric 
mucus glycoprotein, had the greatest quantitative 
effect on the ability of the mucus to retard H § 
diffusion in vitro (3). The viscoelastic properties of 
mucin correlated with its ability to retard H + diffu- 
sion and depended upon hydrophobic domains of 
the mucin protein core and the carbohydrate side 
chains of the mucin molecule (4). The hydrophobic 
regions in gastric mucin are important for lipid 
binding. The lipids bound to mucin have recently 
been demonstrated to protect mucin from oxyradi- 
cal attack, further supporting the protective role of 
lipids in the protective mucous gel (5). 
An evolving body of literature has suggested that 
the phospholipid component of the mucosal barrier 
plays a major role in epithelial defense. The ability 
of a liposomal suspension containing surface active 
phospholipids administered orally to prevent injury 
in pylorus ligated rats before challenge with acid 
has focused considerable attention upon the role of 
phospholipids in mucosal defense (6). The surface 
of the mammalian gastric mucosa has been noted to 
be uniquely hydrophobic and thus nonwettable to 
luminal acid (7). The role of surface hydrophobicity 
in the barrier function of the gastric mucosa has 
been suggested by observing its attenuation after 
the administration of barrier breakers such as bile 
salts and aspirin, and its enhancement by protective 
agents such as prostaglandins (8). The predominant 
surface active phospholipid in pulmonary surfactant 
is dipalmitoylphosphatidylcholine (DPPC). The gas- 
tric mucosa has been observed to contain substan- 
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tial levels of this surface active phospholipid (9). 
This amphipathic molecule is Comprised of two 
saturated fatty acids that allow the creation of a 
tightly packed phospholipid monolayer film, which 
forms a hydrophobic barrier to gastric acid. Al- 
though early descriptions of the hydrophobic bar- 
rier hypothesized that a film composed of DPPC 
directly upon the epithelial cell surface (10), later 
work has clarified the role of the mucous gel as the 
locus of surface hydrophobicity (11, 12). Work in 
our laboratory has confirmed that mucous cells 
synthesize and secrete DPPC in vitro and has sug- 
gested that phospholipid secretion is linked to mu- 
cin secretion (13), augmenting the mucous gel and 
its ability to resist acid. 
Previous studies regarding the effect of sucralfate 
on the mucosal barrier have been limited. Utilizing 
a histochemical technique to measure mucus output 
in rhesus monkeys, sucralfate stimulated the output 
of soluble mucus; this stimulation was not attenu- 
ated by cyclooxygenase inhibition (14). Similarly, 
sucralfate stimulated human gastric bicarbonate se- 
cretion, but this too appeared to be independent of 
its ability to stimulate prostaglandin generation (15). 
These studies suggest that sucralfate may have 
direct effects upon the mucosal barrier, unlike its 
well-studied role in cytoprotection, which is largely 
dependent upon prostaglandin generation. 
Our laboratory has developed an isolated canine 
gastric mucous cell culture system to study the 
physiological regulation of the mucous barrier, and 
we have developed a specific enzyme-linked immu- 
nosorbent assay (ELISA) for gastric mucin (16). 
Utilizing this system, we studied the direct effect of 
sucralfate and its major soluble component, sucrose 
octasulfate (SOS), on the synthesis and release of 
mucin and phospholipid. We correlated these re- 
sults with the effect of sucralfate on mucin synthesis 
and secretion utilizing explants of canine fundus in 
vitro. 
MATERIALS AND METHODS 
The following reagents were purchased from Sigma 
Chemical Company (St. Louis, Missouri): Hanks' bal- 
anced salt solution (HBSS), bovine serum albumin 
(BSA), Ham's F12-Dulbecco's modified Eagle's culture 
medium (F12/DME), N-2-hydroxyethylpiperazine-N'-2- 
ethanesulfonic acid (HEPES), glutamine, collagenase III, 
calcium/magnesium-free Earle's balanced salt solution 
(EBSS), Sepharose CL-4B, antibiotics for cell culture, 
Tween-20, ethylenediaminetetraacetic acid (EDTA), 3,3'- 
diaminobenzidine (DAB), dimethyl sulfoxide (DMSO), 
indomethacin, carbamylcholine chloride (carbachol), 
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phosphotungstic acid (PTA), 2,2'-azino-bis-(3-ethylbenz- 
thiazoline-bisulfonic acid) (ABTS). Trichloracetic acid 
(TCA) was purchased from Fisher Scientific (Livonia, 
Missouri). Diethyl-ether was purchased from Mallinck- 
rodt, Inc. (Paris, Kentucky). Fetal bovine serum (FBS) 
was purchased from Hyclone (Logan, Utah). Silica gel 
plates were purchased from Merck (Darmstadt, Germa- 
ny). The radionuclides [3H]glucosamine (8-30 Ci/mmol), 
and [3H]methyl choline chloride (86.7 Ci/mMol) were 
purchased from New England Nuclear Research Prod- 
ucts (Wilmington, Delaware). The goat anti-rabbit anti- 
body and the Streptavidin-peroxidase reagent were pur- 
chased from Zymed Laboratories (South San Francisco, 
California). The plates used for the immunosorbent as- 
says were 96-well, flat-bottom, tissue culture plates pur- 
chased from Costar (Cambridge, Massachusetts), which 
were read using a Titertek Multiscan plate reader (Flow 
Laboratories, McLean, Virginia). Sucralfate and sucrose 
octasulfate (SOS) powder were gifts of Marion Laborato- 
ries (Kansas City, Missouri). 
Preparation of Primary Culture of Canine Fundic Sur- 
face Epithelial Cells. Dispersed canine gastric epithelial 
cells were prepared by the method of Soll as previously 
described (16). In brief, the stomach was removed from 
an anesthetized mongrel dog, the gastric epithelium 
stripped away and minced, and the cells dispersed using 
EDTA and coltagenase. The dispersed cells were sepa- 
rated into different fractions according to cell size using 
the counterflow elutriation centrifuge (Beckman Instru- 
ments, Arlington Heights, Illinois). By varying the rotor 
speed and elutriation buffer flow rate, five cell fractions 
were generated as a function of cell diameter and have 
been termed C1, C2,3, C4,5, C6,7, and C8,9. Fraction C1 
contains bacteria and cell fragments and was discarded. 
Previous studies have demonstrated that fraction C2,3 is 
enriched in endocrine and mast cells along with mucous 
cells (16). Mucous cells are enriched in C4,5 and C6,7, 
while chief cells are present in C4,5, C6,7, and C8,9, with 
the greatest content in C6,7. Parietal cells are present 
principally in C8,9. Based upon our previous experience 
(13), we chose C4,5, the fraction most enriched with 
mucous cells, for study. 
Metabolic Labeling of Mucin-Associated Phosphatidyl- 
choline. The cells were seeded into 12-well plastic tissue 
culture plates with approximately 4 x 106 cells in 2-3 ml 
of tissue culture media per well, and cultured at 37 ~ C in 
5% CO2, 95% humidified air. The cells were allowed to 
recover from the preparative techniques overnight and 
labeled by the addition of [3H]choline 2 p~Ci/ml (4 ~Ci 
total activity), for a 24-hr loading period. The cells were 
then treated with putative agonist for 1 hr. The media and 
cells were collected separately; floating cells were re- 
moved by centrifugation at 1000g. The [3H]choline- 
labeled phosphatidylcholine was isolated as previously 
described (13). Agonists (sucralfate and SOS) were pre- 
pared in 0.2 M phosphate-buffered saline. 
Quantitation of gastric muein by direct ELISA. The 
isolated cells were cultured in the presence of the putative 
agonist for 24 hr. The media and cells were collected 
together for quantitation of total mucinlike immunoreac- 
tivity. The cells were disrupted with a 5-sec burst from a 
Labline Ultratip sonicator at a setting of 40-60 W and 
centrifuged at 2000g for 10 min to remove particulates. 
This assay has been described in detail previously and 
measures total mucinlike immunoreactivity (MLI), re- 
flecting antigenic determinants requiring both carbohy- 
drate and protein (16). The ELISA was performed by 
loading 100 Ixl of mucin-containing sample onto 96-well 
microtiter plates and incubating overnight at 37 ~ C. Each 
well was then rinsed with "wash buffer" [phosphate- 
buffered saline (PBS) containing 0.05% Tween-20] three 
times and then coated with 200 I~l of 0.5% crystalline 
grade bovine serum albumin for 1 hr at 37 ~ C. Each well 
was again washed three times with wash buffer, and 
incubated with 200 txl of rabbit anti-gastric mucin anti- 
body (at a dilution of 1:2000) in PBS containing 0.05% 
Tween-20 for 1 hr at 37 ~ C. This was rinsed three times 
with wash buffer, 200 i~l of biotinylated goat anti-rabbit 
antibody was added for 1 hr at 37 ~ C, rinsed three times 
with wash buffer, and 200 Ixl of Streptavidin-horseradish 
peroxidase at a concentration of 40 i~g/well in PBS- 
Tween, pH 6.5, was added for 1 hr at 37 ~ C. Each well 
was rinsed three times with wash buffer, and color 
developed by adding ABTS (0.01 g/25 ml) in 100 mM 
sodium citrate buffer, pH 4.2, plus 75 Ixl of 30% H202/ 
ml/25 ml buffer (added immediately prior to use) for 5 
min, in the dark. The antibody binding was determined by 
reading the color developed at 414 nM using a Titertek 
Multiscan multiwell plate reader. 
Indirect ELISA (I-ELISA). This technique is a modifi- 
cation of the method of Mantle et al., which complements 
the above-described direct ELISA and has proven sensi- 
tive for quantitation of small quantities of mucin (17). 
Microtiter plate wells were coated overnight with 500 ng 
(dry mass) purified canine fundic mucin. The wells were 
washed with PBS containing 0.05% Tween-20 and the 
remaining nonspecific binding sites blocked by adding 200 
txl of 0.5% bovine serum albumin. One hundred microli- 
ters of mucin standards (purified mucin 10 ixg/ml-10 
ng/ml) and 100 ~1 mucin-containing samples were prein- 
cubated with 100 I~1 antibody (1:6000 dilution) overnight 
at 37 ~ C, and 75 Ixl was transferred to the mucin-coated 
wells. The wells were washed and biotinylated secondary 
antibody, Streptavidin-horseradish peroxidase, and 
ABTS were added as described above. I-ELISA was 
utilized to quantitate mucin secretion in an aliquot of 
media from isolated cells. 
Glycoprotein Synthesis and Secretion in Canine Fundus 
Explants. In separate experiments designed to examine 
the response of more intact epithelium to stimulation, the 
stomach was removed and the mucosal layer was cut into 
small pieces (2 • 2 mm). Ten tissue pieces were placed in 
each tissue culture well (35 mm diameter) with 2 ml of 
medium consisting of F12/DME, L-glutamine, 15 mM 
HEPES, 7.5% FBS, 7.5% heat-inactivated dog serum, 
and 0.05 mg/ml gentamicin. The explants were incubated 
in the presence of 5 IxCi/well of [3H]glucosamine at 37 ~ C 
under 5% CO2-95% air for 24 hr. The medium was then 
removed and fresh medium added with putative agonist 
for 6 hr. After 2 hr of incubation, an aliquot of the medium 
was removed for assay of secreted glycoprotein, and after 
6 hr of agonist exposure the media and tissue fragments 
were harvested together for quantitation of labeled gly- 
coprotein. 
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Assessment of Glycoprotein Synthesis. At the end of the 
period of incubation, media and tissue fragments were 
harvested together. After homogenization and sonication, 
they were centrifuged at 100,000g at 4~ for 1 hr to 
remove cellular debris. The supernatant was collected 
and the glycoprotein was quantitated. The supernatant 
was precipitated with 10% TCA and 1% PTA at 4~ 
overnight. Then the samples were centrifuged at 500g for 
25 rain and the pellets were resuspended by sonication. 
Each pellet was washed three times with 10% TCA/I% 
PTA and twice with ether-ethanol (3:1). The pellets were 
dissolved in 2 ml of 0.6M KOH and 3H radioactivity was 
measured. 
Measurement of Prostaglandin Ez. Five hundred micro- 
liters of 2-ml media was collected from each unlabeled 
well before and 2 hr after the culture was exposed to 
agonists and immediately frozen at -70  ~ C. PGEE in 
media was quantitated by the University of Michigan 
Diabetes Center, Ligand Core Laboratory, utilizing the 
enzyme immunoassay technique (Cayman Chemical, Ann 
Arbor, Michigan). 
The PGE2 antibody was purchased commercially from 
Cayman Chemical Company. Cross-reactivities with 
other prostaglandins are as follows: 15-keto-PGE2, 9.2%; 
PGE1, 5%; cross-reactivities were less than 0.2% for the 
following prostaglandins: PGA 1, PGB], PGB2, PGD2, 
PGFI,~, 6-keto-PGF]~, PGFe, ~, 13,14-dihydro-15-keto- 
PGFE~, and thromboxane BE (manufacturer specifica- 
tions). PGE z generation was calculated by subtracting 
time zero from the 2-hr value to correct for carry over 
during tissue preparation. 
Data Analysis. The release of mucin-associated phos- 
pholipid after agonist treatment was expressed as cpm in 
the medium divided by the total cpm incorporated (ie, 
percentage of cell content released). The secretion of 
glycoprotein by cultured explants was quantitated in an 
identical fashion, total mucin synthesis was estimated by 
the addition of secreted and tissue associated glycopro- 
tein. Differences between treated and control wells were 
expressed as percentage of control and analyzed by the 
Student's t test for paired data. Differences in mucin-like 
immunoreactivity and increases in PGE2 levels in treated 
and control wells were analyzed similarly. 
RESULTS 
Effects on Phospholipid Secretion. The effect of  
sucralfate and SOS on the release of  surface active 
phospholipid by cultured mucous  cells is shown in 
Figure 1. Sucralfate,  only in the lowest  dose tested, 
led to a significant increase in phospholipid secre- 
tion (123% of  control,  P = 0.02). Indomethacin  
pre t rea tment  significantly decreased the stimula- 
tory effect of  sucralfate on phospholipid secretion 
to 110% of  control,  P = 0.03. SOS, in a non-dose- 
dependent  manner ,  also stimulated phospholipid 
secretion, to 112% of  control at 10 -6 M (Figure 2). 
Indomethac in  pre t rea tment  had no significant effect 
upon the ability of  SOS to release phospholipid. 
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Fig l. Effect of sucralfate (10-7-10 -4 M) on phospholipid release 
by isolated canine gastric mucous cells in culture. INDO = 
indomethacin 10 -5 M *P = 0.02 '~P = 0.03 vs sucralfate 10 -7 M. 
Values are mean -+ standard error, N -> 5. 
These data suggest that sucralfate may  act through 
two mechanisms:  a direct effect of  SOS on the 
mucous cell and an indirect effect, perhaps  linked to 
eicosanoid generation. 
Effects on Mucin Synthesis and Secretion. Expo-  
sure of  isolated mucous  cells in culture to sucralfate 
(10-3-10 -7 M) or SOS ( 1 0 - 4 1 0  -7 M) for 24 hr had 
no effect on mucin synthesis quanti tated by E L I S A  
(N -- 5). Utilizing the indirect E L I S A  to est imate 
the effect on mucin secretion,  neither sucralfate 
10-4-10 -7 M nor SOS 10-4-10 -7 M, significantly 
stimulated mucin secretion above  the increase ob- 
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Fig 2. Effect of SOS (10-7-10 -4 M) on phospholipid release by 
isolated canine gastric mucous cells in culture. INDO = indo- 
methacin 10 5 M. P = 0.02. Values are mean -+ standard error, 
N_>5. 
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TABLE 1. GLYCOPROTEIN SYNTHESIS AND SECRETION IN CANINE FUNDIC 
MUCOSAL EXPLANTS* 
Cell content G!ycoprotein 
secreted P vs synthesis per P vs 
Agent (%, mean +- SEM) control well (dpm) control 
Control 26 -+ 2 1886 +_ 227 
Sucralfate 10 -7 M 27 -+ 2 NS 2032 _+ 183 0.04 
S O S  10 - 6  M 28 _+ 3 NS 1904 + 253 NS 
*Radiolabeled glycoprotein in the media and explants were quantitated by acid 
precipitation. N = 6. 
served in untreated wells (1.52 --- 0.30 to 1.77 --- 0.34 
ixg/ml), while carbachol 10 -5 M stimulated mucin 
secretion from 1.52 +-- 0.30 to 2.21 ___ 0.42 p~g/ml (P 
= 0 . 0 1 ,  N = 5 ) .  
Mucin synthesis was also studied utilizing non- 
dissociated canine fundic mucosal explants. Table 1 
expresses the results for glycoprotein secretion and 
synthesis in response to sucralfate and SOS. No 
significant effect on glycoprotein secretion was ob- 
served in response to sucralfate or SOS to the doses 
tested. With regard to total [3H]glucosamine incor- 
porated into acid precipitable glycoprotein, sucral- 
fate 10 -7 M, stimulated synthesis minimally to 
108% of that observed in untreated explants (N = 
6). 
PGE 2 Release. Isolated canine cells were exposed 
to sucralfate 10 -7 M, SOS 10 -6 M, Or vehicle (PBS) 
for 24 hr in culture. PGE 2 concentrations were 
measured by RIA before and after drug exposure as 
shown in Table 2. No significant increase in PGE 2 
generation was observed in response to any stimu- 
lation (N = 4). 
DISCUSSION 
Sucralfate neither neutralizes secreted acid nor 
alters acid secretion. Therefore, its ability to heal 
gastric and duodenal ulcers has generated interest 
in its mechanism of action. Investigators have iden- 
tified multiple actions of sucralfate, which may 
explain its ability to present acute mucosal injury 
(cytoprotective effects), and promote epithelial re- 
pair and healing. As discussed in a recent review 
(18), sucralfate has been demonstrated to affect 
arachidonic acid metabolism, mucus and bicarbon- 
ate secretion, and tissue growth, regeneration, and 
repair. Sucralfate also has in vitro antipeptic effects 
and may provide a physical barrier (as a polyanion 
gel) between luminal contents and the mucosa, 
impairing the diffusion of acid, pepsin, bile, and 
phospholipases. The relative importance of each of 
these actions to explain the therapeutic efficacy of 
sucralfate remains unknown. 
Sucralfate is also an effective agent for the pro- 
phylaxis of ulcer recurrence (18). This observation 
suggests the drug may augment those factors impor- 
tant in primary epithelial mucosal defense. The 
mucus coat lining the gastric surface epithelium 
provides the first line of defense against the acid- 
peptic activity in the lumen. This mucous gel is 
composed of mucin associated with other proteins 
and lipids (particularly surface active phospholip- 
ids) into which bicarbonate is secreted, forming a 
protective pH gradient. Acid secretion occurs in a 
pulsatile fashion through the mucus gel, allowing 
maintenance of the pH of the mucosa near neutral- 
ity despite the very low luminal pH (19). Since 
sucralfate does not affect acid secretion, its effects 
on the mucosal barrier must be involved in any 
attempt to explain its therapeutic efficacy. 
TABLE 2. PGE 2 PRODUCTION BY CULTURED CANINE MUCOUS CELLS IN RESPONSE TO 
SUCRALFATE OR SOS* 
P value 
Pretreatment Posttreatment vs 
Agent (pg/ml) (pg/ml) -Fold increase control 
Control 4648 _+ 1257 38,724 +_ 11,670 7.81 -+ 95 
Sucralfate 10 -7 M 4607 - 1294 33,365 -+ 10,377 7.53 -+ 1.16 NS 
SOS 10 -6 M 4637 -+ 1211 31,678 - 8,814 7.00 • 2.04 NS 
*Medium was  collected immediately before and 2 hr after drug exposure.  PGE 2 levels 
were measured by  RIA. N = 4. 
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This study has investigated the effect of sucral- 
fate upon components of the mucus gel utilizing 
isolated canine mucous cells in culture and tissue 
explants. We have successfully utilized this model 
previously to probe the physiologic regulation of 
gastric mucin synthesis and surfactant phospholipid 
secretion (13, 16). We observed no direct effect of 
sucralfate or SOS on mucin production or secretion 
by isolated cells in culture. Our data in explant 
culture confirmed these results with the exception 
of a modest increase of 8% in [3H]glucosamine 
incorporation into glycoprotein. Our results differ 
somewhat from other published work on the effect 
of sucralfate on gastric mucus. Prior studies have 
utilized techniques such as total carbohydrate mea- 
surements of aspirated mucus or histochemical 
techniques (14, 20), neither of which are sufficiently 
specific for mucin glycoproteins. These techniques 
are also limited by the effect of sucralfate to influ- 
ence bicarbonate output, which may influence the 
recovery of carbohydrates or increase the apparent 
increase in thickness of secreted mucous gel. 
Our results also differ from those of Slomiany et 
al. (21), who utilized rat epithelial cells exposed to 
sucralfate in vivo, then observed a marked stimula- 
tion of glycoprotein synthesis from tissue explants 
in vitro. We observed modest stimulation of glyco- 
protein synthesis by sucralfate in explants; the 
difference in magnitude may reflect both species 
differences and our technique of drug exposure in 
culture only. It is also possible that the glycoprotein 
increased by sucralfate in the present and prior 
work is not mucin, since this is the first study to use 
a specific immunoassay for gastric mucin for this 
purpose. The lack of effect upon mucin synthesis 
and secretion in isolated cells points to the require- 
ment of an intermediate messenger in intact mu- 
cosa. Based upon our PGE2 results, the intermedi- 
ate for sucralfate action may be another eicosanoid 
or peptide, such as EGF. EGF may stimulate PG 
production by mucosal macrophages (22) and has 
been demonstrated to mediate certain protective 
effects of sucralfate (23). 
We observed that sucralfate and SOS signifi- 
cantly increased surfactant phospholipid release by 
cultured mucous cells. The effect of sucralfate was 
partially inhibited by indomethacin, while the effect 
of SOS was not, suggesting that sucralfate may 
enhance phospholipid release by the direct effect of 
SOS and an indirect effect of sucralfate to stimulate 
eicosanoid formation. Our inability to measure an 
increment in PGE 2 levels after administration of 
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sucralfate and SOS is difficult to explain, especially 
in light of the ability of indomethacin to blunt the 
effect of sucralfate on phospholipid release. Sucral- 
fate may stimulate phospholipid release via another 
mechanism sensitive to cyclooxygenase inhibition 
such as through a different prostaglandin or a leu- 
kotriene. The effects of sucralfate and SOS were 
not dose-dependent. This may reflect the insolubil- 
ity of sucralfate in buffered media; furthermore, 
larger doses of sucralfate left a layer of insoluble 
drug in the well, which may have altered the re- 
sponse of the cells. Of interest, the highest dose of 
SOS (10 -4 M), showed no additional increment in 
phospholipid release. Sucralfate and SOS may also 
act, at least partially, in a non-dose-dependent 
fashion by its irritative manner to cause phospho- 
lipid (and possibly mucus or eicosanoid) release. 
Our findings may explain the recent morphologi- 
cal observation that sucralfate increases the pres- 
ence of surface active phospholipid in lamellar 
bodies found in the gastric lumen of rats (24). This 
corresponds to the observation that sucralfate in- 
creases the viscosity and hydrophobicity of mucin 
and decreases its permeability to H § (25). Although 
other investigators have not observed an enhance- 
ment in mucus phospholipid content in the rat in 
response to sucralfate, these investigators utilized 
entirely different techniques and species (26). 
The implications of the present study suggest 
sucralfate may affect the gastric mucosal barrier in 
a largely qualitative manner. Increasing surface 
active phospholipid secretion may enhance the bar- 
rier function of gastric mucus. Previous work by 
other investigators has suggested that sucralfate 
may interact directly with gastric mucus to enhance 
its viscosity and resistance to H + permeation on a 
physical basis (27). The mechanism through which 
sucralfate and SOS act on the mucous cell is still 
unclear. Our studies do not implicate PGE2 as an 
important intermediate for the synthesis or release 
of mucin; the dose relationship raises doubt regard- 
ing the presence of a specific receptor for sucralfate 
or SOS. Our data suggest the drug may work as a 
local irritant, perhaps causing direct membrane 
pertubation, the generation of secondary messen- 
gers, and effects on the mucus barrier. This hypoth- 
esis is consistent with the previous observation that 
sucralfate activates phosphoinositide turnover in 
the gastric mucosa (21). Additional efforts are re- 
quired to understand the action of sucralfate at the 
cellular level. Sucralfate and SOS have minimal 
effects on isolated gastric mucous cells. The corn- 
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plexity of gastric epithelium suggests that one must 
also address issues of submucosal blood flow, cel- 
lular restitution, and other processes that require 
the intact organ for an integrated response. 
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